Plain-English translation of NCT06755450 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Phase 1 β Testing in a small group (usually 20β80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a first-in-human study testing a new medication called in patients with relapsed advanced lymphomas and chronic lymphocytic leukemia. Researchers will gradually increase the dose to find the safest and most effective level. The goal is to understand how the medication works in the body and whether it shows promise for treating blood cancers that have come back.
Many patients with advanced lymphomas exhaust available treatment options or experience disease relapse. This medication represents a new approach to treating these cancers, and this early-stage trial aims to establish whether this treatment is safe enough and biologically active enough to pursue in larger patient populations.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
You will take by mouth once daily, starting at a low dose. The dose will gradually increase in small groups of participants as researchers monitor safety. You will have regular clinic visits for blood tests, physical exams, and scans to track how you respond and watch for side effects. The study is designed to find the right dose and gather information about how the medication behaves in your body.
AI-generated summary from trial data Β· Jul 18, 2026 Β· Not medical advice
India